| |
Unlock the key to seamless eCOA integration for your next clinical trial with IQVIA’s comprehensive Licensing Guide. From understanding licensing requirements to optimizing integration, our guide is your roadmap to streamlined eCOA implementation.
|
|
Today’s Big NewsMar 8, 2024 |
| By Annalee Armstrong Eli Lilly’s donanemab has been delayed at the FDA for approval in Alzheimer’s disease, a blow to the company’s efforts to get what could be a $2.8 billion per year opportunity by 2028. |
|
|
|
By Annalee Armstrong President Joe Biden urged Congress to adopt a $12 billion plan to fund women’s health research, including conditions like rheumatoid arthritis, menopause, Alzheimer’s disease and endometriosis. |
By Nick Paul Taylor AbbVie has cut short its call on the ADAM family. The ADAM9-targeted antibody-drug conjugate MGC936 fell short of safety and efficacy expectations in solid tumors, prompting AbbVie and its equal partner MacroGenics to walk away from the candidate. |
Sponsored by Wacker Biotech Sitting down with Guido Seidel, Managing Director of Wacker Biotech, we explore some of the key challenges, opportunities and innovations for pharmaceutical companies to consider in mRNA manufacturing. |
|
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Secure 50% off Your Fierce TMF Summit Pass | LIMITED Passes Available: Use Promo Code LAST25. Secure your spot Today!
|
|
By James Waldron Kronos Bio has made its second round of layoffs in five months, with another fifth of the biotech’s workforce heading to the exits as the company focuses on a CDK9 inhibitor. |
Sponsored by NYCEDC Ready to shape the future of life sciences? Discover how NYC's strategic investments are driving change. |
By Gabrielle Masson Sellas Life Sciences Group is sending two executives out the door in efforts to optimize resources and advance clinical programs, including a phase 3 cancer vaccine being studied for patients with acute myeloid leukemia. |
Sponsored by ICON Biotech ICON Biotech survey shows that although challenges remain, optimism returns to strategically savvy biotech innovators |
By Max Bayer DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash. |
By Helen Floersh A new paper in Nature Biotechnology offers the first in-depth look at how Insilico Medicine used artificial intelligence to discover, develop and test its lead drug candidate. |
By Max Bayer,Gabrielle Masson BioMarin has found its new commercial chief just in time to help reinvigorate sales. Longtime BioNTech exec Marett is retiring. GSK poaches Flagship CEO-Partner Austin after Lepore exit. |
By Ayla Ellison,Conor Hale,Andrea Park In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
By Kevin Dunleavy After reporting the failure of a confirmatory trial of its amyotrophic lateral sclerosis drug Relyvrio (AMX0035), Amylyx Pharmaceuticals is uncertain whether it will pull the treatment from the market in the U.S. and in Canada, where it is known as Albrioza. |
By Dave Muoio After appealing to voters on reproductive care access, the president celebrated and called for expansions to the Inflation Reduction Act and promised to protect the Affordable Care Act from attacks. |
By Conor Hale Researchers may have found a way to make the invisible visible when it comes to detecting small yet life-threatening complications after surgery. |
By Angus Liu Eisai presented updated projections for Alzheimer's disease drug Leqembi. Sumitomo Pharma initiated a round of layoffs in the U.S. Kyowa Kirin is building a new biologics facility in North Carolina. And more. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
